Boao, Feb. 28 (Reporter Yuan Yu) On Feb. 28, a reporter from Hainan Daily learned from the Bureau of the Lecheng International Medical Tourism Pilot Zone in Boao, Hainan that CStone Pharmaceuticals’ first-of-its-kind drug, Avonib, recently Approved in the Lecheng Pioneer Zone for clinically urgently needed treatment for previously treated adult patients with locally advanced or metastatic cholangiocarcinoma harboring isocitrate dehydrogenase-1 (IDH1) mutations. This will bring new treatment options for domestic cholangiocarcinoma patients who are in urgent need of treatment.
According to reports, ivonib is an oral small-molecule inhibitor targeting IDH1 mutations. It can reversibly bind to mutant IDH1 to reduce the level of alpha-hydroxyglutarate and promote normal cell differentiation. , thereby exerting an anti-tumor effect. The drug was approved by the U.S. Food and Drug Administration in August 2021 for the treatment of previously treated adult patients with locally advanced or metastatic cholangiocarcinoma harboring an IDH1 mutation detected by an FDA-approved test.
Currently, the treatment for patients with IDH1-mutant cholangiocarcinoma is limited, and the approval of ivonib will bring more benefits to these patients.
Ivornib is the first and only drug approved by the U.S. Food and Drug Administration for targeted therapy in patients with IDH1-mutated cholangiocarcinoma. Selected in the 2021 edition of the “CSCO Guidelines for the Diagnosis and Treatment of Biliary Tumors”, etc.